Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Celgene

Status and phase: Completed; Phase 3

Conditions: Non-Small Cell Lung Carcinoma

Treatments: Drug: Paclitaxel; Drug: Carboplatin; Drug: Albumin-bound paclitaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT00540514

CA031

Details and patient eligibility

About

The purpose of this study is to compare disease response of Albumin-bound paclitaxel (ABI-007) plus Carboplatin versus Taxol and Carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC).

Enrollment: 1,052 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed stage IIIB or IV non-small cell lung cancer (NSCLC)

• Male or non-pregnant and non-lactating female, and equal or greater than age 18

  • If a female patient is of child-bearing potential, as evidence by regular menstrual periods, she must have a negative serum pregnancy test (beta human chorionic gonadotropin [βhCG]) documented within 72 hours of the first administration of study drug
  • If sexually active, the patient must agree to utilize contraception considered adequate and appropriate by the investigator

• No other current active malignancy

• Radiographically-documented measurable disease (defined by the presence of at least 1 radiographically documented measurable lesion)

• Patients must have received no prior chemotherapy for the treatment of metastatic disease. Adjuvant chemotherapy permitted providing cytotoxic chemotherapy was completed 12 months prior to starting the study

• Patient has the following blood counts at baseline:

  • Absolute neutrophil count (ANC) greater than or equal to 1.5x10^9/L
  • Platelets greater than or equal to 100x10^9/L
  • Hemoglobin (Hgb) greater than or equal to 9 g/dL

• Patient has the following blood chemistry levels at baseline:

  • Aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT) less than or equal to 2.5 x upper limit of normal range (ULN) or less than or equal to 5.0 x ULN if liver metastases;
  • Total bilirubin less than or equal to ULN
  • Creatinine less than or equal to 1.5 mg/dL

• Expected survival of greater than 12 weeks

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent form prior to participation in any study-related activities

Exclusion criteria

• Evidence of active brain metastases, including leptomeningeal involvement. Prior evidence of brain metastasis permitted only if treated and stable and off therapy for greater than or equal to 1 month
• The only evidence of disease is non-measurable
• Patient has pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology Criteria for Adverse Events [CTCAE] Version 3).
• Patient received radiotherapy in the last 4 weeks, except if to a non-target lesion only. Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed
• Patient has a clinically significant concurrent illness
• Patient has received treatment with any investigational drug within the previous 4 weeks
• Patient has a history of allergy or hypersensitivity to any of the study drugs
• Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug
• Patient is enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

1,052 participants in 2 patient groups

Albumin-bound paclitaxel + Carboplatin

Experimental group

Description:

Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m\^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg\*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.

Treatment:

Drug: Carboplatin

Drug: Albumin-bound paclitaxel

Paclitaxel + Carboplatin

Active Comparator group

Description:

Participants received 200 mg/m\^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg\*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.

Treatment:

Drug: Carboplatin

Drug: Paclitaxel